SARcode has announced that its SAR 1118 molecule has shown positive results in a Phase II Study of dry eye disease.

SAR 1118 is an integrin antagonist that inhibits T-cell mediated inflammation, a key component of dry eye disease.

The results of the trial, which involved 230 patients with dry eye disease, indicated that the subjects receiving SAR 1118 experienced a reduction in corneal staining, increased tear production and improved visual-related function compared to the placebo.

SARcode Corporation chief medical officer Charles Semba said that the company is encouraged by the clinical effects of SAR 1118 in improving both the signs and symptoms of dry eye, which supports the broad anti-inflammatory mechanism of the molecule.